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Contrast-Induced Nephropathy
A Clinical and Evidence-Based Approach
Martin Tepel, MD; Peter Aspelin, MD; Norbert Lameire, MD
Contrast medium–induced nephropathy (CIN) is a com-mon cause of acute renal dysfunction. During the past
few years, several publications have provided clinical and
experimental data on this topic. Our review focuses on 4
major concerns of CIN relevant in clinical practice: (1) What
is the evidence that CIN is a clinically relevant and a
dangerous condition for the patient? (2) Is there a difference
in CIN rate among different contrast media, and how is that
related to the physicochemical properties of different avail-
able contrast media? (3) What is the evidence that peripro-
cedural hydration is an effective, appropriate, and safe
method to prevent CIN? (4) What is the evidence for the use
of a drug, in particular acetylcysteine, to prevent CIN?
Clinical Relevance
CIN has gained increased attention in the clinical setting,
particularly during cardiac intervention but also in many
other radiological procedures in which iodinated contrast
media are used. There is at present good clinical evidence
from well-controlled randomized studies that CIN is a com-
mon cause of acute renal dysfunction.1,2 CIN is the acute
deterioration of renal function after parenteral administration
of radiocontrast media in the absence of other causes. CIN is
generally defined as an increase in serum creatinine concen-
tration of 0.5 mg/dL (44 mol/L) or 25% above baseline
within 48 hours after contrast administration.3–7
Although the exact mechanisms of CIN have yet to be fully
elucidated, several causes have been described. Increased
adenosine-, endothelin-, and free radical–induced vasocon-
striction and reduced nitric oxide– and prostaglandin-induced
vasodilatation have been observed. These mechanisms cause
ischemia in the deeper portion of the outer medulla, an area
with high oxygen requirements and remote from the vasa
recta supplying the renal medulla with blood. Contrast agents
also have direct toxic effects on renal tubular cells, causing
vacuolization, altered mitochondrial function, and apoptosis.8
Atopy does not play a role in the pathogenesis of CIN.
The incidence of CIN in the general population has been
calculated to be 2%. In high-risk patients, ie, patients with
chronic renal impairment, diabetes mellitus, congestive heart
failure, and older age, the incidence has been calculated to be
20% to 30%.3–7 CIN has been associated with increased
morbidity, extended length of hospital stay, and increased
costs.9 Several risk factors have been described for CIN.10–12
A risk score for prediction of CIN after percutaneous coro-
nary intervention has been reported by Mehran et al.12 That
risk score includes hypotension (5 points, if systolic blood
pressure 80 mm Hg for at least 1 hour requiring inotropic
support), use of intra-aortic balloon pump (5 points), conges-
tive heart failure (5 points, if class III/IV by New York Heart
Association classification or history of pulmonary edema),
age (4 points, if 75 years), anemia (3 points, if hematocrit
39% for men and 36% for women), diabetes mellitus (3
points), contrast media volume (1 point per 100 mL), esti-
mated glomerular filtration rate (GFR; GFR in mL/min per
1.73 m2; 2 points, if GFR 60 to 40; 4 points, if GFR 40 to 20;
6 points, if GFR 20). A risk score of 6, 6 to 10, 11 to 16,
and 16 indicates a risk for CIN of 7.5%, 14%, 26%, and
57%, respectively.12 It should be emphasized that higher
contrast volume is an important risk factor for CIN.10–12
Although no definite proof has been obtained yet, the risk of
nonsteroidal antiinflammatory drugs or angiotensin-
converting enzyme inhibitors to exacerbate CIN has been
reported because of their effects on renal perfusion or
tubulotoxicity.13,14 It is thus clear that CIN is a potentially
harmful condition. The reason that problems seem to be
increasing is that the number of angiographies and CT
examinations in clinical practice is increasing, and today
higher doses are administered to sicker and older
patients.3–7,15
Is There a Difference in CIN Between
Different Contrast Media? How Is That
Related to Their Physicochemical Properties?
Physicochemical Properties of Contrast Agents
In 1968 Almén proposed new, low-toxicity, nonionic, mono-
meric and dimeric contrast media, and since then the toxicity
of different contrast media has mainly been attributed to their
osmolality, viscosity, and chemotoxicity.8,16–21
Contrast media today are commonly divided into high-
osmolar, low-osmolar, and iso-osmolar contrast media. The
osmolality value is often expressed in terms of the ratio
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between the number of iodine atoms and the number of
dissolved particles. The higher the ratio, the better is the
attenuation of x-rays because there are more iodine atoms for
fewer particles of contrast agent. Contrast agents with a ratio
of 1.5:1 are monomeric ionic and hyperosmolar with an
osmolality in the range of 1000 to 2000 mOsm/kg. Nonionic
monomeric or ionic dimeric contrast media with a ratio of 3:1
are low-osmolar contrast media, with an osmolality in the
range of 500 to 1000 mOsm/kg. Contrast media with a ratio
of 6:1 are nonionic dimeric iso-osmolar with an osmolality in
the range of 290 to 300 mOsm/kg, ie, iso-osmolar with
plasma. Iso-osmolar nonionic contrast media have reduced
osmolality because of the creation of a dimer, linking 2
molecules of contrast agent together through a common side
chain and thereby increasing the size of the molecule in
solution. On the basis of experimental studies in rats in
particular, it has been argued that the high viscosity of the
dimeric iso-osmolar contrast media could be a disadvan-
tage.8,20 However, direct measurements in rats with micro-
electrodes showed a similar reduction of the medullary
oxygen tension after administration of either the low-osmolar
contrast agent iopromide (viscosity 5 mPas) or the
iso-osmolar contrast agent iotrolan (viscosity 8.5
mPas).20
Direct chemical toxicity is mainly dependent on the phys-
icochemical properties of contrast media. A recent in vitro
study revealed that in addition to the osmolality of the agent,
a direct cytotoxic effect of the molecule could contribute to
its cytotoxic effects.21 However, when the agent was dis-
solved to equal urine concentrations, no difference in cyto-
toxicity could be demonstrated between the dimeric iso-
osmolar contrast media and the low-osmolar contrast media.
When, however, the agents were administered in iso-osmolar
concentrations, the dimeric contrast media had a higher
cytotoxic effect than the low-osmolar contrast media. One
should keep in mind that in clinical investigations a patient
usually receives a contrast agent in equal iodine concentra-
tions and that in the human kidney the molar concentration of
the dimer is only half that of a low-osmolar contrast agent.
Clinical Studies Comparing High- and
Low-Osmolar Contrast Media
With the introduction of low-osmolar and iso-osmolar contrast
media, a reduction in the incidence of CIN has been observed.3–7
Low-osmolar contrast media have gained widespread clinical
acceptance because of fewer adverse effects than high-osmolar
contrast media, particularly in high-risk patients with an elevated
preprocedural serum creatinine.22–27 It should be remembered,
however, that several initial studies did not show significant
differences in CIN between low-osmolar and high-osmolar
contrast media (Table 1). This has been attributed to the small
numbers of high-risk patients, ie, patients with preexisting renal
insufficiency, included in these studies. Finally, the prospective,
randomized trial by Rudnick et al24 clearly demonstrated that
patients with preexisting renal insufficiency alone or combined
with diabetes mellitus had a significantly lower risk of CIN
when low-osmolar contrast media are used. Subsequently, a
meta-analysis of 25 trials with available data revealed a pooled
odds ratio of CIN with low-osmolar contrast media of 0.61 (95%
CI, 0.48 to 0.77) times that with high-osmolar contrast media.
Furthermore, for patients with preexisting renal insufficiency,
this odds ratio was 0.5 (95% CI, 0.36 to 0.68), whereas it was
0.75 (95% CI, 0.52 to 1.10) in patients without prior renal
insufficiency.27
Clinical Studies Comparing Iso-Osmolar and
Low-Osmolar Contrast Media
Several studies have included both iso-osmolar and low-
osmolar contrast media when investigating the incidence of
TABLE 1. Randomized Trials Comparing Contrast Media With Different Osmolalities
First Author
and Reference Year Pt. No. Procedure Contrast Media Used CIN, n/N (%) ARR, % RR Significance
Barrett22 1992 249 Coronary angiography LOCM (iohexol)
HOCM (diatrizoate)
5/132 (3.8)
8/117 (6.8)
3.0 0.55 0.39
Moore23 1992 929 AngiographyCT LOCM (iohexol)
HOCM (diatrizoate)
13/479 (2.7)
13/450 (2.9)
0.2 0.94 1.0
Rudnick24 1995 1183 Coronary angiography LOCM (iohexol)
HOCM (diatrizoate)
19/591 (3.2)
42/592 (7.1)
3.9 0.45 0.003
Schwab25 1989 443 Coronary angiography LOCM (iopamidol)
HOCM (diatrizoate)
24/235 (10.2)
17/208 (8.2)
2.0 1.25 0.51
Taliercio26 1991 307 Coronary angiography LOCM (iopamidol)
HOCM (diatrizoate)
12/155 (7.7)
29/152 (19.1)
11.4 0.43 0.008
Aspelin28 2003 129 Coronary angiography IOCM (iodixanol)
LOCM (iohexol)
2/64 (3.1)
17/65 (26.1)
23.0 0.12 0.002
Chalmers29 1999 102 Angiography IOCM (iodixanol)
LOCM (iohexol)
2/54 (3.7)
5/48 (10.4)
6.7 0.35 0.25
Hardiek30 2003 102 Coronary angiographyangiography IOCM (iodixanol)
LOCM Iopamidol
7/54 (13.0)
10/48 (20.8)
7.8 0.62 0.30
Jo31 2005 281 Coronary angiography IOCM (iodixanol)
LOCM (ioxaglate)
10/164 (6.1)
18/117 (15.4)
9.3 0.40 0.01
Pt indicates patient; ARR, absolute risk reduction; RR, relative risk; LOCM, low-osmolar contrast media; HOCM, high-osmolar contrast media; and IOCM, iso-osmolar
contrast media.
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CIN.28–31 In the Nephrotoxicity in High-Risk Patients Study
of Iso-Osmolar and Low-Osmolar Non-Ionic Contrast Media
(NEPHRIC) by Aspelin et al,28 the iso-osmolar contrast agent
iodixanol induced significantly less increase in serum creat-
inine than the low-osmolar contrast agent iohexol in patients
with diabetes mellitus and chronic renal failure. The peak
increase in serum creatinine between days 0 and 3 compared
with baseline was significantly lower in the iodixanol than in
the iohexol group (1119 versus 4887 mol/L; P0.001).
The incidence of CIN was 3.1% in the iso-osmolar contrast
group compared with 26.2% in the low-osmolar contrast
group (relative risk, 0.12; 95% CI, 0.03 to 0.50; P0.002).
An increase in serum creatinine of 88 mol/L (1.0 mg/dL)
did not occur in any of the subjects in the iso-osmolar contrast
group but occurred in 10 subjects (15.4%) in the low-osmolar
contrast group. Another study indicating a reduced incidence
of CIN with iso-osmolar iodixanol was published by Chalm-
ers and Jackson29 in patients with chronic renal failure
undergoing angiography, one third of whom had diabetes
mellitus. In the study by Hardiek et al,30 7 of 54 patients
undergoing CT (13.0%) in the iso-osmolar contrast group had
CIN compared with 10 of 48 patients (20.8%) in the low-
osmolar contrast (iopamidol) group (relative risk, 0.62; 95%
CI, 0.25 to 1.51; P0.30). In coronary angiography/percuta-
neous coronary intervention, Jo et al31 showed in a prospec-
tive, randomized study that 10 of 164 patients (6.1%) in the
iso-osmolar contrast media group developed CIN compared
with 18 of 117 patients (15.4%) in the low-osmolar contrast
group (relative risk, 0.40; 95% CI, 0.19 to 0.83; P0.01).
When only patients with diabetes and impaired renal function
were included, CIN in the iodixanol group was 8.2% and
25%, respectively.31 Solomon32 showed that the incidence of
CIN was significantly lower in patients receiving iodixanol or
iopamidol than in those receiving iohexol. In conclusion, it
has been demonstrated that the iso-osmolar contrast media
exhibit lower nephrotoxic properties more than the low-
osmolar media in a population of patients at very high risk in
the NEPHRIC study.28 We agree, however, with the editorial
of Sandler33 that randomized controlled studies are needed to
confirm these differences.
Evidence for Periprocedural Hydration
Textbooks recommend periprocedural hydration as a simple
and effective means to prevent CIN. However, no large
prospective, randomized trial of deliberate hydration versus
no intervention for the prevention of CIN has been conducted,
and therefore several questions remain. An early study by
Eisenberg et al34 showed that hydration with 550 mL normal
saline plus 250 mL heparinized saline flush per hour pre-
vented CIN in 537 patients undergoing cerebral, abdominal,
or peripheral angiography with the use of high-osmolar
contrast media. However, that retrospective study lacked
randomization and an appropriate control group. Surpris-
ingly, another early study on 364 patients undergoing angiog-
raphy did not find a preventive effect of hydration on CIN.35
Should fluids be administered intravenously or orally? On
the one hand, Trivedi et al36 compared the effects of intrave-
nous normal saline at a rate of 1 mL/kg per hour for 24 hours
beginning 12 hours before contrast administration versus
hydration with unrestricted oral fluids on the incidence of
CIN. One of 27 patients (3.7%) in the intravenous saline
group suffered from CIN compared with 9 of 26 patients
(34.6%) in the orally hydrated group (relative risk, 0.11; 95%
CI, 0.02 to 0.79; P0.005). On the other hand, a randomized
prospective study in 36 patients showed that the administra-
tion of 0.45% normal saline given intravenously at a rate of
75 mL/h for 24 hours beginning 12 hours before contrast
administration had similar effects on the increase in serum
creatinine compared with oral hydration with 1000 mL clear
liquid over 10 hours plus 0.45% normal saline at 300 mL/h
for 6 hours beginning just before contrast administration.37
Can a forced diuresis with maintenance of intravascular
volume reduce CIN? At least 2 prospective, randomized trials
addressed that question. Solomon et al38 showed that CIN in
patients with preexisting renal insufficiency undergoing per-
cutaneous coronary angiography occurred in 3 of 28 patients
(10.7%) who received intravenous 0.45% saline. By contrast,
CIN developed in 7 of 25 patients (28.0%) who received
intravenous saline plus 25 g mannitol (P0.16 compared
with saline) and in 10 of 25 patients (40.0%) who received
intravenous saline plus 80 mg furosemide (P0.02 compared
with saline). Stevens et al39 showed that in patients with
preexisting renal insufficiency and undergoing percutaneous
coronary intervention, CIN occurred in 17 of 55 patients
(30.9%) who received intravenous fluid hydration (0.45%
saline at a rate of 150 mL/h), in 7 of 21 patients (33.3%) who
received intravenous fluid hydration plus 1 mg/kg furosemide
plus 3 g/kg per min dopamine, and in 7 of 22 patients
(31.8%) who received intravenous fluid hydration plus furo-
semide plus dopamine plus mannitol, showing no significant
differences between all groups. From these studies, it can be
concluded that forced diuresis is not superior compared with
hydration with saline alone to prevent CIN. Neither mannitol
nor furosemide nor dopamine offered any additional benefit
beyond the hydration protocol.
Which type of fluid should be used for periprocedural
hydration? In a large, prospective, randomized trial, 5 of 685
patients (0.7%) given isotonic 0.9% saline but 14 of 698
patients (2.0%) given 0.45% saline developed CIN (P0.042
by 2 test).40 Merten et al41 showed in patients with preexist-
ing renal insufficiency undergoing diagnostic or interven-
tional procedures requiring low-osmolar contrast media that
CIN occurred in 1 of 60 patients (1.7%) receiving intravenous
154 mmol/L sodium bicarbonate but in 8 of 59 patients
(13.6%) who received intravenous 154 mmol/L sodium
chloride (relative risk, 0.12; 95% CI, 0.02 to 0.95; P0.02).
In summary, despite the fact that formal prospective,
randomized studies in humans proving the superiority of
preeminent hydration are lacking, current limited evidence
supports periprocedural hydration with preferably intrave-
nous administration of 0.9% isotonic saline or an isotonic
sodium bicarbonate solution, without furosemide, mannitol,
or dopamine.
Evidence for Prevention of CIN by Drugs or
Other Procedures
Acetylcysteine: Randomized Controlled Trials
Because of its favorable side effect profile, low costs, and
some positive results of randomized studies, acetylcysteine
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has gained favor in clinical practice as a preventive therapy in
high-risk groups, ie, patients with preexisting renal insuffi-
ciency.5 Trials performed over the past 5 years with this drug,
however, have provided conflicting results. Table 2 summa-
rizes data from these prospective, randomized trials.42–66
Several prospective, randomized trials showed that the ad-
ministration of acetylcysteine along with hydration signifi-
cantly reduced CIN in high-risk patients, whereas other trials
TABLE 2. Randomized Trials Evaluating Use of Acetylcysteine for Prevention of CIN
First Author
and
Reference Year
Pt
No.
Diabetes,
% Procedure
Acetylcysteine
Dose and
Duration, d
Baseline Serum
Creatinine,
mg/dL
Placebo Group,
Incidence of
CIN, n/N (%)
Acetylcysteine
Group, Incidence of
CIN, n/N (%)
ARR,
% RR
Signifi-
cance
Adamian42 2002 47 33-57 Coronary angiography
PCI
600 mg BID 2.1 9/42 (21) 1/35 (3) 18 0.13 0.02
Baker43 2003 80 41-44 Coronary angiography
PCI
IV 150 mg/kg, before;
plus 50 mg/kg for 4 h
1.8 8/39 (21) 2/41 (5) 16 0.24 0.045
Briguori44
(subgroup of
CM 140
mL)
2002 120 NA Coronary angiograph
yPCIangiography
600 mg BID, 2 d NA 5/60 (8) 0/60 (0) 8 0 0.05
Briguori45 2004 223 43-41 Coronary angiography
PCIangiography
Standard dose 600 mg
BID, 2 d; double dose
1200 mg BID, 2 d
1.6 (Standard
dose)
12/109 (11)
(Double dose)
4/114 (4)
7 0.32 0.04
Briguori46 2004 192 52-50 Coronary angiography
PCIangiography
1200 mg BID, 2 d;
vs fenoldopam 0.10
g/kg per minute
1.7 (Fenoldopam)
13/95 (14)
(Double dose)
4/97 (4)
10 0.30 0.02
Diaz-
Sandoval47
2002 54 21 Coronary angiography 600 mg BID, 2 d 1.6 13/29 (45) 2/25 (8) 37 0.20 0.01
Efrati48 2003 49 53 Coronary angiography 1000 mg BID, 2 d 1.5 2/25 (5) 0/24 (0) 5 0 0.49
Kay49 2003 200 36-39 Coronary angiography
PCI
600 mg BID, 2 d 1.4 12/98 (12) 4/102 (4) 8 0.32 0.03
MacNeill50 2003 43 36-57 Coronary angiography 600 mg BID, 2 d 1.9 7/22 (32) 1/21 (5) 27 0.15 0.046
Miner51 2004 180 67-68 Coronary angiography
PCI
2000 mg BID, 2 d 1.5 19/85 (22) 9/95 (10) 12 0.37 0.04
Shyu52 2002 121 64-63 Coronary angiography
PCI
400 mg BID, 2 d 2.8 15/61 (25) 2/60 (3) 22 0.14 0.001
Tepel53 2000 83 33 CT 600 mg BID, 2 d 2.4 9/42 (21) 1/41 (2) 19 0.11 0.01
Allaqaband54 2002 85 50 Coronary angiography
PCI
600 mg BID, 2 d 2.1 6/40 (15) 8/45 (18) 3 1.19 0.78
Boccalandro55 2003 179 61-49 Coronary angiography 600 mg BID, 2 d 1.9 13/106 (12) 10/73 (14) 2 1.11 0.82
Briguori44
(total study)
2002 183 43-33 Coronary angiography
PCIangiography
600 mg BID, 2 d 1.5 10/91 (11) 6/92 (7) 4 0.59 0.31
Durham56 2002 79 46-50 Coronary angiography 1200 mg 1 h before
and 3 h after
2.2 9/41 (22) 10/38 (26) 4 1.20 0.80
Fung57 2004 91 NA Coronary angiography
PCI
400 mg tid, 2 d 2.3 6/45 (13) 8/46 (17) 4 1.30 0.77
Goldenberg58 2004 80 49-39 Coronary angiography
PCI
600 mg tid, 2 d 2.0 3/39 (8) 4/41 (10) 2 1.20 0.79
Gomes59 2005 156 52-52 Coronary angiography
PCI
600 mg BID, 2 d 1.3 8/79 (10) 8/77 (10) 0 1.03 1.00
Kefer60 2003 104 13 Coronary angiography IV 1200 mg 1.1 3/51 (6) 2/53 (8) 2 1.56 0.68
Loutrianakis61 2003 47 NA Coronary angiography 600 mg BID, 2 d NA 3/23 (13) 8/24 (33) 20 1.92 0.33
Ochoa62 2004 80 Coronary angiography
PCI
1000 mg BID, 2 h 2.0 11/44 (25) 3/36 (8) 17 0.33 0.08
Oldemeyer63 2003 96 49-41 Coronary angiography
PCI
1500 mg BID, 2 d 1.6 3/47 (6) 4/49 (8) 2 1.28 1.00
Tadros64 2003 110 NA Coronary angiography 600 mg BID, 2 d NA 9/55 (16) 3/55 (5) 11 0.13
Vallero65 2002 20 NA Coronary angiography
PCI
600 mg BID, 2 d 1.5 0/8 (0) 2/12 (17) 17 NA 0.52
Webb66 2004 349 31-39 Coronary angiography
PCI
IV 500 mg immediately
before CM
1.6 47/180 (21) 51/169 (23) 2 1.12 0.55
Pt indicates patient; diabetes, patients with diabetes mellitus (%) in placebo group and in acetylcysteine group; ARR, absolute risk reduction; RR, relative risk; PCI,
percutaneous coronary intervention; CM, contrast media; and NA, not given. To convert serum creatinine to mol/L, multiply by 88.4.
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could not show a beneficial additional effect. What are the
reasons for these contradictory results? Many prospective
randomized trials used several different procedures, different
types and volumes of contrast media, different timing and
dosage of acetylcysteine administration, and different routes
(intravenous or oral) of administration. The study by Briguori
et al45 emphasized the importance of acetylcysteine dosage.
Their study indicated that the administration of a double dose
of acetylcysteine (1200 mg twice daily) was superior com-
pared with a standard dose of 600 mg twice daily. Baker et
al43 showed that the intravenous administration of high-dose
acetylcysteine was also effective. However, some questions
on the use of acetylcysteine arose from a nonrandomized
study that investigated different markers of renal function
after administration of acetylcysteine to healthy subjects
without exposure to contrast agents. That study showed that
in healthy subjects acetylcysteine reduced serum creatinine
by 3.5%, serum urea by 7.7%, and cystatin C concentrations
by 1.3%. These findings may indicate that acetylcysteine may
also affect creatinine or urea metabolism.67
Acetylcysteine: Meta-Analyses
Data from several meta-analyses68–76 on the effect of acetyl-
cysteine are summarized in Table 3. The first meta-analysis
by Birck et al68 showed that, compared with periprocedural
hydration alone, the administration of acetylcysteine signifi-
cantly reduced the risk of CIN in patients with preexisting
renal insufficiency. Isenbarger et al69 reported a similar result.
The meta-analysis by Alonso et al,70 including 8 prospective,
randomized trials published in full-text articles and 4 addi-
tional studies published in abstract form, showed that acetyl-
cysteine significantly reduces the risk for CIN. Bagshaw and
Ghali71 analyzed 14 angiography trials including 1261 pa-
tients and reported a relative risk of 0.54 (95% CI, 0.32 to
0.91; P0.02). The meta-analysis by Pannu et al,72 including
15 prospective, randomized trials, showed that acetylcysteine
significantly reduced CIN. However, these authors further
noted a significant heterogeneity in the acetylcysteine effect
across trials.71,72 The meta-analysis of Kshirsagar et al,73
including data from 15 published and 1 unpublished trial,
described evidence of heterogeneity, thus precluding reliance
on a meaningful summary effect estimate. Nallamothou et
al74 showed a nonsignificant trend toward benefit in patients
treated with acetylcysteine. The meta-analysis by Liu et al,75
analyzing 9 prospective, randomized trials, showed that
acetylcysteine significantly reduced the risk of CIN (relative
risk, 0.43; 95% CI, 0.24 to 0.75). The recent meta-analysis of
Duong et al76 included 14 trials with 1584 patients and also
showed that acetylcysteine significantly reduced the risk for
developing CIN (relative risk, 0.57; 95% CI, 0.37 to 0.84;
P0.01). In summary, it has been stated that a large placebo-
controlled trial might be helpful to resolve the question of
acetylcysteine for the prevention of CIN. At present there is
limited evidence that acetylcysteine together with adequate
hydration may be useful as standard prophylactic procedure
in patients at high risk for CIN.
Other Drugs and Procedures to Prevent CIN
Other drugs and procedures have been suggested to prevent
CIN, including ascorbic acid, theophylline, fenoldopam, cal-
cium antagonists, and periprocedural hemofiltration. Spargias
et al77 showed in a prospective randomized study in patients
with preexisting renal insufficiency that CIN occurred in 11
of 118 patients (9%) receiving 7 g ascorbic acid but in 23 of
113 patients (20%) in the control group (relative risk, 0.46;
95% CI, 0.23 to 0.90; P0.02). The effect of theophylline on
CIN has been investigated in a meta-analysis by Bagshaw and
Ghali.78 They included 9 randomized controlled trials show-
ing evidence of heterogeneity of results across the trials. The
overall pooled odds ratio was 0.40 (95% CI, 0.14 to 1.16;
P0.09), indicating no significant prophylactic effect of
theophylline on CIN.78 In the CONTRAST study, CIN
occurred in 46 of 137 patients (34%) receiving the selective
dopamine-1 agonist fenoldopam intravenously and in 44 of
146 patients (30%) in the control group (relative risk, 1.11;
95% CI, 0.79 to 1.57; P0.61), indicating no preventive
effect.79 Calcium antagonists have been used to prevent CIN;
however, most studies did not show a significant prophylactic
effect of calcium antagonist on CIN.80–82 Current evidence
does not support the use of postprocedural hemodialysis for
TABLE 3. Meta-Analyses of Randomized, Prospective Trials on Effect of Acetylcysteine for Prevention of CIN
First Author and
Reference
Year of
Publication
No. of Trials Included
in Meta-Analysis
References of Trials Included
in Meta-Analysis
Relative Risk
(95% CI)
Birck68 2003 7 44, 47, 49, 52, 53, 54, 56 0.435 (95% CI, 0.215-0.879)
Isenbarger69 2003 7 44, 47, 49, 52, 53, 54, 56 0.370 (95% CI, 0.160-0.840)
Alonso70 2004 12 43, 44, 47, 49, 52, 53, 54, 56 0.550 (95% CI, 0.340-0.910)
Bagshaw71 2004 14 43, 44, 47, 48, 49, 50, 52, 54, 56, 57, 58, 60, 63, 65 0.540 (95% CI, 0.320-0.910)
Pannu72 2004 15 43, 44, 47, 49, 52, 54, 53, 56, 61, 62, 63, 65 0.650 (95% CI, 0.430-1.000)
Kshirsagar73 2004 16 42, 44, 47, 49, 52, 53, 54, 55, 56, 58, 61, 63, 65 ND
Nallamothu74 2004 20 43, 44, 47, 48, 49, 50, 52, 53, 54, 56, 57, 58, 61, 62, 63, 65 0.730 (95% CI, 0.520-1.000)
Liu75 2005 9 43, 44, 47, 49, 52, 53, 54, 56, 62 0.430 (95% CI, 0.240-0.750)
Duong76 2005 14 44, 47, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 63, 64 0.570 (95% CI, 0.370-0.840)
ND indicates not determined. First author (reference), year of publication, No. and references of included trial, and relative risk (95% CI) are given for the 9
meta-analyses. The meta-analysis by Alonso et al70 included 4 additional studies published as abstracts. The meta-analysis by Pannu et al72 included 3 additional
studies published as abstracts or in press. The meta-analysis by Kshirsagar et al73 used unpublished data and data from abstracts and did not report summary data
for relative risk and CIs. The meta-analysis by Nallamothu et al74 included 4 additional studies published as abstracts.
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prevention of CIN.83 However, periprocedural hemofiltration
given in an intensive care unit setting appears to be effective
in preventing CIN (3 of 58 patients [5%] versus 28 of 56
patients [50%]; relative risk, 0.10; 95% CI, 0.03 to 0.32;
P0.0001) and is associated with improved in-hospital and
long-term outcomes.84 However, periprocedural hemofiltra-
tion is an invasive and costly procedure that is not directly
applicable to all high-risk patients who are exposed to
contrast agents for simpler procedures.
Conclusions
In summary, CIN is a common cause of acute renal functional
impairment and accounts for significant morbidity and mor-
tality. Patients with chronic renal failure, diabetes mellitus,
congestive heart failure, older age, hypotension, and anemia
are at particular risk. The primary goal should be to avoid
contrast media to prevent CIN, if at all possible, and risk
factors should be recognized. Prospective, randomized trials
identified significant differences between contrast agents due
to their physicochemical properties, and low-osmolar or
iso-osmolar contrast media should be used to prevent CIN in
at-risk patients. The volume of contrast media should be as
low as possible. Current evidence supports periprocedural
hydration with preferably intravenous administration of 0.9%
isotonic saline or an isotonic sodium bicarbonate solution.
There is limited evidence that any pharmaceutical interven-
tion, eg, acetylcysteine, may prevent CIN.
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